GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies
This article was originally published in The Pink Sheet Daily
Witty discussed crucial local subjects like product patent policies, capping foreign direct investments, valuations of pharmaceutical assets and GSK's plans for the Indian market.
You may also be interested in...
Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies
MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations
Long Search Ends For Sanofi As It Buys Universal Medicare's Nutraceutical Brands In India
MUMBAI - French drug maker Sanofi's long search for high-growth OTC brands in India finally materialized as it announced the acquisition of Mumbai-headquartered Universal Medicare Pvt. Ltd.'s nutraceutical businesses
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).